Otsuka's Phase 3 rare kidney disease data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 6 June, 2025

Discover seamless global drug distribution with Marken. sponsored by Marken

presented by Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py in Chi­na

news Biopharma leaders carving a path for the industry’s LGBTQ+ community Otsuka spells out Phase 3 win in rare kidney disease, Vera’s stock takes a hit Peer Review GSK taps Sanofi vet to lead vaccine R&D; Bristol Myers names head of corporate affairs Biotech ranks as China’s best shot to surpass US in emerging tech, report finds

Cytiva and EurekaBio Form Strategic Partnership to Advance Lentiviral Vector Manufacturing for Cell and Gene Therapy in China sponsored by EurekaBio

ENDPOINTS PHARMA FDA's Makary looks at ways to speed drug approvals, talks about cutting user fees Omada Health is going public on Friday at a $1.1B valuation Trump's health appointees pledge support for cell and gene therapies at FDA roundtable A decade after its ill-fated $40.5B megadeal, Teva pivots from generics to innovation FDA's Prasad explains rationale behind pausing Valneva's chikungunya vaccine in seniors

Jun 18 12:00pm ET Illuminating the CKD patient journey: Clinicogenomic data reshapes research & drug discovery sponsored by Natera Jun 24 10:30am ET Expanding access, accelerating trials: The power of community-based oncology research sponsored by START Research Jun 26 11:00am ET May the (Power of the) Pool be with you: Accelerating time from DNA to GMP – STI based CLD Platform sponsored by Rentschler Biopharma

in case you missed it 1. Exclusive: Tech VC Amplify raises $200M for first biotech fund, hires Elliot Hershberg as new partner 2. Anne Wojcicki and Regeneron set to duke it out in restarted 23andMe auction 3. Regenxbio says Duchenne gene therapy improved motor skills in five patients 4. Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis 5. Exclusive: Allay reaches $57.5M Series D milestone for post-surgical pain drug 6. US COVID vaccine recommendations sow confusion among doctors, insurers